Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06637072 · ClinicalTrials.gov registry record · Phase 4

A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC

A Phase 4 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by argenx.

Active
Registry status
Phase 4
Development phase
23
Enrollment target
13
Study locations

NCT06637072 is a Phase 4 study of Chronic Inflammatory Demyelinating Polyneuropathy that is active but no longer recruiting, run by argenx. The registered enrollment target is 23 participants, below the 158-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (85% lower). The trial reports 13 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06637072, a Phase 4 study of Chronic Inflammatory Demyelinating Polyneuropathy, is active but no longer recruiting, sponsored by argenx.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
23 participants
Enrollment target
13
Study locations

Study Summary

This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.

Conditions Studied

Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

  • BIOLOGICAL Efgartigimod PH20 SC

Study Locations (13)

Texas

  • National Neuromuscular Research Institute - Austin
  • Horizon Clinical Research: Gill Neuroscience - Cypress
  • Northwest Houston Neurology - Cypress - Cypress
  • Cedar Health Research - Dallas - Dallas

Florida

  • Neurology Associates PA - Maitland
  • Visionary Investigators Network - Miami

Tennessee

  • Erlanger Neuroscience Institute - Chattanooga
  • Vanderbilt University Medical Center - Nashville

District of Columbia

  • MedStar Washington Hospital Center - Washington D.C.

Illinois

  • Northwestern Memorial Hospital - Chicago

Louisiana

  • Velocity Clinical Research - Lafayette

Michigan

  • SRI International - ClinEdge - Plymouth

North Carolina

  • Velocity Clinical Research - Raleigh

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2024-12-10
Est. Completion 2026-02-23
Phase Phase 4

Sponsor

argenx

49 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06637072

The ClinicalTrials.gov registry entry for NCT06637072 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 158-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (85% lower). The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 1 intervention - of which Efgartigimod PH20 SC is the first listed.

NCT06637072 reports 13 study locations spanning 8 distinct geographic areas - top geographies include Texas, Florida, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06637072 about?

NCT06637072 is a clinical study titled "A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC". This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.

What is the current status of trial NCT06637072?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2024-12-10. Estimated completion is 2026-02-23.

What conditions does trial NCT06637072 study?

This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy.

What interventions are being tested in trial NCT06637072?

The interventions under investigation include: Efgartigimod PH20 SC (BIOLOGICAL).

Who is sponsoring clinical trial NCT06637072?

This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06637072 being conducted?

This trial has 13 study locations across District of Columbia, Florida, Illinois, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Inflammatory Demyelinating Polyneuropathy

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.